APP and Alzheimer disease: As a result, a large number of AD therapeutic strategies have focused on APP or Aβ (Karran and De Strooper, 2022; Zhang et al., 2023), with the recent success of anti-amyloid monoclonal antibodies hinting at the potential of this approach (Budd Haeberlein et al., 2022; van Dyck et al., 2023; Sims et al., 2023).